Loading...
XASXPTX
Market cap24mUSD
Jan 09, Last price  
0.05AUD
1D
0.00%
1Q
8.70%
Jan 2017
-41.13%
Name

Prescient Therapeutics Ltd

Chart & Performance

D1W1MN
XASX:PTX chart
P/E
—
P/S
10.85
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
26.92%
Rev. gr., 5y
17.64%
Revenues
4m
+52.89%
1,420,000209,0003,532,000521,000000008,142251,0851,002,5001,224,241939,7711,647,7591,029,3371,185,4761,889,3362,428,1233,712,364
Net income
-8m
L+17.61%
-3,999,000-4,625,000-2,667,000-1,773,000-1,346,000-1,864,000-1,362,000-1,892,3701,787,000-1,296,896-2,133,375-1,754,142-2,567,633-2,573,730-3,797,227-3,321,189-4,148,818-5,117,176-7,004,501-8,238,049
CFO
-7m
L+19.49%
00000000-29,180-1,127,309-2,240,655-1,558,914-3,278,240-2,149,126-4,195,468-2,317,182-3,970,025-4,312,657-6,191,003-7,397,907
Dividend
Oct 21, 19930.05 AUD/sh
Earnings
Feb 21, 2025

Profile

Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of various cancers in Australia. Its lead drug candidate is PTX-200, which is in Phase 2a clinical trial for HER2-negative breast cancer, Phase IB/2 clinical trial in relapsed and refractory AML, and Phase 1b in recurrent or persistent platinum-resistant ovarian cancer; and PTX-100, a RhoA inhibitor, for hematological and solid malignancies that focuses on cancers with Ras and RhoA mutations. It has a strategic collaboration with The University of Texas MD Anderson Cancer Center to develop blood cancer binder for OmniCAR. The company was formerly known as Virax Holdings Limited and changed its name to Prescient Therapeutics Limited in December 2014. Prescient Therapeutics Limited was incorporated in 1986 and is based in Melbourne, Australia.
URL
https://ptxtherapeutics.com/
IPO date
Dec 19, 1986
Employees
3
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑062015‑06
Income
Revenues
3,712
52.89%
2,428
28.52%
1,889
59.37%
Cost of revenue
10,899
9,886
7,099
Unusual Expense (Income)
NOPBT
(7,186)
(7,458)
(5,210)
NOPBT Margin
Operating Taxes
(3,712)
(2,368)
(1,751)
Tax Rate
NOPAT
(3,474)
(5,090)
(3,459)
Net income
(8,238)
17.61%
(7,005)
36.88%
(5,117)
23.34%
Dividends
Dividend yield
Proceeds from repurchase of equity
18
16,526
594
BB yield
-0.06%
-28.04%
-0.59%
Debt
Debt current
330
Long-term debt
Deferred revenue
Other long-term liabilities
47
Net debt
(14,183)
(21,915)
(12,284)
Cash flow
Cash from operating activities
(7,398)
(6,191)
(4,313)
CAPEX
(4)
Cash from investing activities
12,000
(16,000)
(4)
Cash from financing activities
18
15,828
428
FCF
(4,915)
(4,730)
(3,484)
Balance
Cash
14,513
21,915
12,284
Long term investments
Excess cash
14,328
21,794
12,189
Stockholders' equity
18,067
26,075
16,762
Invested Capital
4,076
4,288
4,620
ROIC
ROCE
EV
Common stock shares outstanding
805,311
727,527
647,801
Price
0.04
-53.09%
0.08
-47.74%
0.16
-36.73%
Market cap
30,602
-48.07%
58,930
-41.31%
100,409
-33.01%
EV
16,419
37,014
88,125
EBITDA
(7,186)
(7,456)
(5,209)
EV/EBITDA
Interest
7
Interest/NOPBT